CollPlant Biotechnologies (CLGN)
(Delayed Data from NSDQ)
$2.77 USD
+0.52 (23.11%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $2.72 -0.05 (-1.81%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Fundamental Charts
About Return on Equity (TTM)
CollPlant Biotechnologies Ltd. Sponsored ADR's return on equity, or ROE, is -87.33% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.08%. While this shows that CLGN has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
CLGN 2.77 +0.52(23.11%)
Will CLGN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CLGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLGN
CollPlant (CLGN), Stratasys Initiate Study for Breast Implants
Ascendis Pharma (ASND) Surges 8.7%: Is This an Indication of Further Gains?
CLGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CLGN
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR SECOND QUARTER FINANCIAL RESULTS | CLGN Stock News
CollPlant Appoints Collagen Biomaterials Expert as New Head of North America Commercial ...
CLGN: Shareholder Sales Won't Benefit Company Directly | CLGN Stock News
CollPlant files to sell 1.27M ordinary shares for holders
CollPlant files to sell 1.27M ordinary shares for holders